Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
Provided By GlobeNewswire
Last update: Oct 15, 2024
NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)’s annual meeting, 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.
3.29
+0.9 (+37.66%)
Find more stocks in the Stock Screener
GALT Latest News and Analysis
2 days ago - ChartmillThese stocks are moving in today's sessionKeep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.
3 days ago - ChartmillWhich stocks are moving on Tuesday?Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
